These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31340855)

  • 1. The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy.
    Sabio E; Chan TA
    Genome Med; 2019 Jul; 11(1):43. PubMed ID: 31340855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
    Duan J; Wang Y; Jiao S
    Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
    Linette GP; Carreno BM
    Curr Hematol Malig Rep; 2019 Aug; 14(4):286-291. PubMed ID: 31187421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
    Wilky BA
    Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Gide TN; Wilmott JS; Scolyer RA; Long GV
    Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
    Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
    Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
    Varricchi G; Loffredo S; Marone G; Modestino L; Fallahi P; Ferrari SM; de Paulis A; Antonelli A; Galdiero MR
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
    Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
    Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
    Xia Y; Medeiros LJ; Young KH
    Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.
    Allard B; Allard D; Stagg J
    Methods Mol Biol; 2016; 1458():159-77. PubMed ID: 27581021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils.
    Zheng X; Zhang N; Qian L; Wang X; Fan P; Kuai J; Lin S; Liu C; Jiang W; Qin S; Chen H; Huang Y
    Int J Cancer; 2020 Mar; 146(6):1730-1740. PubMed ID: 31840816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can rituximab unlock the innate potential of checkpoint blockade in the CNS?
    Rubenstein JL
    Leuk Lymphoma; 2019 Feb; 60(2):281-283. PubMed ID: 30188237
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokines and cancer: new immune checkpoints for cancer therapy.
    Karin N
    Curr Opin Immunol; 2018 Apr; 51():140-145. PubMed ID: 29579623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
    Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
    Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Rivera Vargas T; Apetoh L
    Front Immunol; 2019; 10():1181. PubMed ID: 31191545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.